PDS Biotechnology Corp Investment Income, Nonoperating
PDS Biotechnology Corp (PDSB) reported Investment Income, Nonoperating of $871.88 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-21.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2019-02-21
- PDS Biotechnology Corp investment income, nonoperating for the quarter ending 2018-12-31 was $175.84K, a 20.65% decline year-over-year.
- PDS Biotechnology Corp investment income, nonoperating for the quarter ending 2018-09-30 was $187.26K, a 12.52% decline year-over-year.
- PDS Biotechnology Corp investment income, nonoperating for the quarter ending 2018-06-30 was $262.14K, a 55.14% increase year-over-year.
- PDS Biotechnology Corp investment income, nonoperating for the quarter ending 2018-03-31 was $246.64K, a 156.22% increase year-over-year.
- PDS Biotechnology Corp investment income, nonoperating for fiscal 2018 was $871.88K, a 24.39% increase from fiscal 2017.
- PDS Biotechnology Corp investment income, nonoperating for fiscal 2017 was $700.90K, a 230.15% increase from fiscal 2016.
- PDS Biotechnology Corp investment income, nonoperating for fiscal 2016 was $212.30K, a 2237.07% increase from fiscal 2015.
- PDS Biotechnology Corp investment income, nonoperating for fiscal 2015 was $9.08K, a 208.87% increase from fiscal 2014.
| Period end | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month | Investment Income, Nonoperating 12 month |
|---|---|---|---|---|
| 2018-12-31 | $175.84K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $363.10K derived: sum of 2 quarters · filed 2019-02-21 | $625.24K derived: sum of 3 quarters · filed 2019-02-21 | $871.88K 10-K · filed 2019-02-21 |
| 2018-09-30 | $187.26K 10-Q · filed 2018-11-01 | $449.40K derived: sum of 2 quarters · filed 2018-11-01 | $696.03K 10-Q · filed 2018-11-01 | $917.64K derived: sum of 4 quarters · filed 2019-02-21 |
| 2018-06-30 | $262.14K 10-Q · filed 2018-08-01 | $508.78K 10-Q · filed 2018-08-01 | $730.38K derived: sum of 3 quarters · filed 2019-02-21 | $944.45K derived: sum of 4 quarters · filed 2019-02-21 |
| 2018-03-31 | $246.64K 10-Q · filed 2018-05-01 | $468.25K derived: sum of 2 quarters · filed 2019-02-21 | $682.31K derived: sum of 3 quarters · filed 2019-02-21 | $851.28K derived: sum of 4 quarters · filed 2019-02-21 |
| 2017-12-31 | $221.61K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $435.67K derived: sum of 2 quarters · filed 2019-02-21 | $604.64K derived: sum of 3 quarters · filed 2019-02-21 | $700.90K 10-K · filed 2019-02-21 |
| 2017-09-30 | $214.06K 10-Q · filed 2018-11-01 | $383.04K derived: sum of 2 quarters · filed 2018-11-01 | $479.30K 10-Q · filed 2018-11-01 | $543.32K derived: sum of 4 quarters · filed 2018-11-01 |
| 2017-06-30 | $168.97K 10-Q · filed 2018-08-01 | $265.23K 10-Q · filed 2018-08-01 | $329.26K derived: sum of 3 quarters · filed 2018-08-01 | $385.34K derived: sum of 4 quarters · filed 2018-08-01 |
| 2017-03-31 | $96.26K 10-Q · filed 2018-05-01 | $160.29K derived: sum of 2 quarters · filed 2018-05-01 | $216.37K derived: sum of 3 quarters · filed 2018-05-01 | $265.74K derived: sum of 4 quarters · filed 2018-05-01 |
| 2016-12-31 | $64.03K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $120.11K derived: sum of 2 quarters · filed 2018-03-01 | $169.49K derived: sum of 3 quarters · filed 2018-03-01 | $212.30K 10-K · filed 2018-03-01 |
| 2016-09-30 | $56.08K 10-Q · filed 2017-11-01 | $105.46K derived: sum of 2 quarters · filed 2017-11-01 | $148.27K 10-Q · filed 2017-11-01 | $154.55K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $49.38K 10-Q · filed 2017-08-01 | $92.19K 10-Q · filed 2017-08-01 | $98.46K derived: sum of 3 quarters · filed 2018-03-01 | $99.80K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $42.81K 10-Q · filed 2017-05-03 | $49.09K derived: sum of 2 quarters · filed 2018-03-01 | $50.42K derived: sum of 3 quarters · filed 2018-03-01 | $51.76K derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $6.27K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $7.61K derived: sum of 2 quarters · filed 2018-03-01 | $8.95K derived: sum of 3 quarters · filed 2018-03-01 | $9.08K 10-K · filed 2018-03-01 |
| 2015-09-30 | $1.33K 10-Q · filed 2016-11-01 | $2.67K derived: sum of 2 quarters · filed 2016-11-01 | $2.81K 10-Q · filed 2016-11-01 | $3.16K derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-06-30 | $1.34K 10-Q · filed 2016-08-03 | $1.48K 10-Q · filed 2016-08-03 | $1.83K derived: sum of 3 quarters · filed 2017-03-02 | $2.72K derived: sum of 4 quarters · filed 2017-03-02 |
| 2015-03-31 | $139.00 10-Q · filed 2016-05-03 | $488.00 derived: sum of 2 quarters · filed 2017-03-02 | $1.38K derived: sum of 3 quarters · filed 2017-03-02 | |
| 2014-12-31 | $349.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $1.24K derived: sum of 2 quarters · filed 2017-03-02 | $2.94K 10-K · filed 2017-03-02 | |
| 2014-09-30 | $895.00 10-Q · filed 2015-11-06 | $2.59K 10-Q · filed 2015-11-06 | ||
| 2013-12-31 | $3.95K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |